Nona Biosciences has announced a strategic collaboration with Kodiak Sciences to advance the discovery of innovative multi-target antibodies for treating ophthalmic diseases. The partnership leverages Nona’s proprietary Harbour Mice® platform, known for its fully human antibody capabilities.
Under this agreement, Kodiak Sciences secures the rights to utilise the H2L2 and HCAb Harbour Mice® platforms across multiple therapeutic antibody discovery and development programmes. This partnership underscores the value and potential of Nona’s cutting-edge Harbour Mice® technology.
The collaboration aims to accelerate the development of next-generation biotherapeutics by combining the expertise of both companies to deliver innovative treatments to patients in need.
Nona’s Harbour Mice® platform is capable of generating fully human monoclonal antibodies in two formats the two heavy and two light chains (H2L2) format, and the heavy chain-only (HCAb) format. This eliminates the need for further engineering or humanisation.
Notably, the HCAb Harbour Mice® platform is revolutionising antibody development by producing unique, fully human heavy chain-only antibodies. These antibodies, approximately half the size of conventional IgGs, offer significant advantages for next-generation antibody therapies.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!